Myelofibrosis is a rare type of bone marrow cancer that affects blood cell production and causes scarring in the bone marrow. It usually presents in older people and can develop into leukaemia over time. CALR is recurrently mutated in myelofibrosis, creating a surface‐exposed neoepitope that could be a valuable target for new drug discovery and development, taking advantage of the specific neo-epitope.
Funded since: 2023 & 2024
AusHealth partners: CALHN and University of Adelaide
Status: Pre-clinical studies underway.